tert-butyl 3-azido-4-hydroxypyrrolidine-1-carboxylate | 203434-45-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: tert-butyl 3-azido-4-hydroxypyrrolidine-1-carboxylate
• 英文别名: tert-butyl 3-azido-4-hydroxypyrrolidinyl-1-carboxylate；Tert-butyl 3-azido-4-hydroxyl pyrrolidinyl-1-carboxylate
• CAS: 203434-45-1
• 化学式: C₉H₁₆N₄O₃
• mdl: MFCD24391040
• 分子量: 228.251
• InChiKey: CSWBTQKOSPXYIE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  64.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 3-azido-4-hydroxypyrrolidine-1-carboxylate 在 platinum(IV) oxide 氢气 作用下， 以 甲醇 为溶剂， 反应 26.0h， 生成 (3S,4S)-N-Boc-3-氨基-4-羟基吡咯烷
  参考文献：
  名称：

  Practical Synthesis of Enantiopure Cyclic 1,2-Amino Alcohols via Catalytic Asymmetric Ring Opening of Meso Epoxides

  摘要：

  DOI：

  10.1021/jo970146p
• 作为产物：
  描述：

  N-Boc-3-吡咯啉 在 sodium azide 、 氯化铵 、 间氯过氧苯甲酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 37.0h， 生成 tert-butyl 3-azido-4-hydroxypyrrolidine-1-carboxylate
  参考文献：
  名称：

  Synthesis of new (±)-1-(4-(3-fluorobenzyloxy)pyrrolidin-3-yl)-4-phenyl-1H-1,2,3-triazole derivatives via Click reaction and study of anti-cancer activity against HCT 116, MDA-MB231, Mia-PaCa2 Cell lines

  摘要：

  一系列16个新的(±)-1-(4-(3-氟苄氧基)吡咯烷-3-基)-4-苯基-1H-1,2,3-三唑衍生物是从2,5-二氢-1H-吡咯合成得到的。这16个化合物通过它们的1H NMR、13C NMR和质谱数据得到了良好的表征。这些化合物的抗癌活性针对HCT 116、MDA-MB231、Mia-PaCa2癌细胞系进行了测试。在这些化合物系列中，8b表现出最高的活性，对MDA-MB231细胞系的IC50值为42.5 μg/mL。化合物8o和8n显示出中等活性，对HCT-116和Mia-PaCa2癌细胞系的IC50值分别为64.3 μg/mL和68.4 μg/mL。

  DOI：

  10.21608/ejchem.2019.16652.2014

文献信息

• PURINE DERIVATIVES
  申请人：PFIZER INC.

  公开号：US20150141402A1

  公开（公告）日：2015-05-21

  The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R 1 , R 2 , R 3 , R 4 , R 5 , R 5a , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , and m are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

  本发明涉及式(I)的化合物或其药用盐，其中Q、G、环A、环B、R1、R2、R3、R4、R5、R5a、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18、R19、R20、R21、R22、R23、R24和m在此定义。这些新颖的嘌呤衍生物在治疗哺乳动物中的异常细胞生长，如癌症方面具有用途。另外，还涉及含有这些化合物的药物组合物，以及在治疗哺乳动物中的异常细胞生长方面使用这些化合物和组合物的方法。
• [EN] ERK INHIBITORS<br/>[FR] INHIBITEURS D'ERK
  申请人：MERCK SHARP & DOHME

  公开号：WO2016100050A1

  公开（公告）日：2016-06-23

  The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.

  本发明提供了一种化合物(I)或其药学上可接受的盐、酯和前药，这些化合物是ERK2抑制剂。该发明还提供了一种包括至少一种化合物(I)和药学上可接受的载体的有效量的药物组合物。该发明还提供了一种包括至少一种化合物(I)的有效量和至少一种其他药学活性成分的有效量（例如，化疗药物等）以及药学上可接受的载体的药物组合物。
• Synthesis of new (±)-1-(4-(3-fluorobenzyloxy)pyrrolidin-3-yl)-4-phenyl-1H-1,2,3-triazole derivatives via Click reaction and study of anti-cancer activity against HCT 116, MDA-MB231, Mia-PaCa2 Cell lines
  作者：HARI BABU Bollikolla、Ravi Kumar g、s n murthy b、Santha Kumari m

  DOI：10.21608/ejchem.2019.16652.2014

  日期：2020.2.18

  A series of 16 new (±) -1-(4-(3-fluorobenzyloxy) pyrrolidin-3-yl)-4-phenyl-1H-1,2,3-triazole derivatives were synthesized from 2,5-dihydro-1H-pyrrole. Sixteen compounds are well characterized by their 1H NMR, 13C NMR and mass spectral data. Anticancer activities of these compounds were tested against HCT 116, MDA-MB231, Mia-PaCa2 cancer cell lines. Among these series of compounds, 8b exhibited highest activity with IC50 of 42.5 µg/ mL against MDA-MB231 cell line. The compound 8o and 8n showed moderate activity with IC50 of 64.3 µg/ mL and 68.4 µg/ mL against HCT -116 and Mia-PaCa2 cancer cell lines respectively.

  一系列16个新的(±)-1-(4-(3-氟苄氧基)吡咯烷-3-基)-4-苯基-1H-1,2,3-三唑衍生物是从2,5-二氢-1H-吡咯合成得到的。这16个化合物通过它们的1H NMR、13C NMR和质谱数据得到了良好的表征。这些化合物的抗癌活性针对HCT 116、MDA-MB231、Mia-PaCa2癌细胞系进行了测试。在这些化合物系列中，8b表现出最高的活性，对MDA-MB231细胞系的IC50值为42.5 μg/mL。化合物8o和8n显示出中等活性，对HCT-116和Mia-PaCa2癌细胞系的IC50值分别为64.3 μg/mL和68.4 μg/mL。
• [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRAZOLO[1,5-A]PYRIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE LA KINASE RET
  申请人：ANDREWS STEVEN W

  公开号：WO2018071454A1

  公开（公告）日：2018-04-19

  Provided herein are compounds of the Formula I: (I) or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

  本文提供了Formula I的化合物：(I)或其药用可接受的盐或溶剂，其中A、B、X1、X2、X3、X4、环D、E、Ra、Rb、n和m的含义如规范中所述，它们是RET激酶的抑制剂，并且在治疗和预防可以用RET激酶抑制剂治疗的疾病中非常有用，包括与RET相关的疾病和紊乱。
• Tricyclic triazolic compounds
  申请人：Laboratorios del Dr. Esteve S.A.

  公开号：EP2070933A1

  公开（公告）日：2009-06-17

  The present invention relates to new tricyclic triazolic compounds having a high affinity for sigma-1 receptor as well as to the process for the preparation thereof, to composition comprising them and to their use as medicaments according to compounds of formula (I) Wherein R1 and R2 are as defined in the description.

  本发明涉及具有高亲和力的新三环三唑化合物与sigma-1受体的关系，以及其制备过程，包括它们的组成物和根据式(I)化合物的用途。 其中R1和R2如描述中所定义。